{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:25:14Z","timestamp":1793816714337,"version":"4.6.1"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hepatitis B virus (HBV) is a hepatotropic virus, which damage to hepatocytes is not direct, but through the immune system. HBV specific CD4<jats:sup>+<\/jats:sup> T cells can induce HBV specific B cells and CD8<jats:sup>+<\/jats:sup> T cells. HBV specific B cells produce antibodies to control HBV infection, while HBV specific CD8<jats:sup>+<\/jats:sup> T cells destroy infected hepatocytes. One of the reasons for the chronicity of HBV infection is that it cannot effectively activate adoptive immunity and the function of virus specific immune cells is exhausted. Among them, virus antigens (including HBV surface antigen, e antigen, core antigen, etc.) can inhibit the function of immune cells and induce immune tolerance. Long term nucleos(t)ide analogues (NAs) treatment and inactive HBsAg carriers with low HBsAg level may \u201cwake up\u201d immune cells with abnormal function due to the decrease of viral antigen level in blood and liver, and the specific immune function of HBV will recover to a certain extent, thus becoming the \u201cdominant population\u201d for functional cure. In turn, the functional cure will further promote the recovery of HBV specific immune function, which is also the theoretical basis for complete cure of hepatitis B. In the future, the complete cure of chronic HBV infection must be the combination of three drugs: inhibiting virus replication, reducing surface antigen levels and specific immune regulation, among which specific immunotherapy is indispensable. Here we review the relationship, mechanism and clinical significance between the cure of hepatitis B and immune system.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1075916","type":"journal-article","created":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:25:21Z","timestamp":1668680721000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":69,"title":["Hepatitis B functional cure and immune response"],"prefix":"10.3389","volume":"13","author":[{"given":"Jia-Rui","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Long","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"B1","unstructured":"Hepatitis b2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis b virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis b - report from the 2019 EASL-AASLD HBV treatment endpoints Conference(\u2021)","volume":"72","author":"Cornberg","year":"2020","journal-title":"J Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.007","article-title":"The guidelines of prevention and treatment for chronic hepatitis b (2019 version)","volume":"27","author":"Wang","year":"2019","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2022.00289","article-title":"An ideal hallmark closest to complete cure of chronic hepatitis b patients: High-sensitivity quantitative HBsAg loss","author":"Wang","year":"2022","journal-title":"J Clin Trans Hepatology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.3390\/ijms23031552","article-title":"Hepatitis b flare in hepatitis b e antigen-negative patients: A complicated cascade of innate and adaptive immune responses","volume":"23","author":"Chang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i9.881","article-title":"Innate and adaptive immune escape mechanisms of hepatitis b virus","volume":"28","author":"Zhao","year":"2022","journal-title":"World J Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.coviro.2021.06.006","article-title":"Gut microbiota in the innate immunity against hepatitis b virus - implication in age-dependent HBV clearance","volume":"49","author":"Wu","year":"2021","journal-title":"Curr Opin Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis b","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J Hepatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7643","DOI":"10.3390\/ijms22147643","article-title":"HBsAg dampened STING associated activation of NK cells in HBeAg-negative CHB patients","volume":"22","author":"Zheng","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.618196","article-title":"Hepatitis b surface antigen suppresses the activation of nuclear factor kappa b pathway via interaction with the TAK1-TAB2 complex","volume":"12","author":"Deng","year":"2021","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25718","article-title":"GP73 facilitates hepatitis b virus replication by repressing the NF-\u03baB signaling pathway","author":"Liu","year":"2020","journal-title":"J Med Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.02896.x","article-title":"Hepatitis b virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis b virus","volume":"126","author":"Op","year":"2009","journal-title":"Immunology."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.42","article-title":"T-Cell exhaustion in chronic hepatitis b infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms18071517","article-title":"Programmed cell death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) in viral hepatitis","volume":"18","author":"Cho","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325915","article-title":"Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients","author":"Zhang","year":"2022","journal-title":"Gut"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis b virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1136\/gutjnl-2018-316644","article-title":"Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection","volume":"68","author":"Hoogeveen","year":"2019","journal-title":"Gut."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI92812","article-title":"Hepatitis b virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J Clin Invest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.24272\/j.issn.2095-8137.2018.013","article-title":"Animal models for the study of hepatitis b virus infection","volume":"39","author":"Guo","year":"2018","journal-title":"Zool Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211838","article-title":"Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV","volume":"219","author":"Fang","year":"2022","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/cells10051114","article-title":"CD4(+) T cells in chronic hepatitis b and T cell-directed immunotherapy","volume":"10","author":"Buschow","year":"2021","journal-title":"Cells-Basel."},{"key":"B28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.intimp.2017.02.019","article-title":"Th17\/Treg imbalance and increased interleukin-21 are associated with liver injury in patients with chronic severe hepatitis b","volume":"46","author":"Liu","year":"2017","journal-title":"Int Immunopharmacol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039307","article-title":"Significance of the balance between regulatory T (Treg) and T helper 17 (Th17) cells during hepatitis b virus related liver fibrosis","volume":"7","author":"Li","year":"2012","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20649","article-title":"Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis b virus infection","volume":"41","author":"Stoop","year":"2005","journal-title":"Hepatology."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104251","article-title":"Role of orally induced regulatory T cells in immunotherapy and tolerance","volume":"359","author":"Bertolini","year":"2021","journal-title":"Cell Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.12.006","article-title":"Regulatory T cells control antigen-specific expansion of tfh cell number and humoral immune responses via the coreceptor CTLA-4","volume":"41","author":"Wing","year":"2014","journal-title":"Immunity."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100398","article-title":"Humoral immunity in hepatitis b virus infection: Rehabilitating the b in HBV","volume":"4","author":"Vanwolleghem","year":"2022","journal-title":"JHEP Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41426-018-0034-0","article-title":"Use of ELISpot assay to study HBs-specific b cell responses in vaccinated and HBV infected humans","volume":"7","author":"Tian","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i21.5769","article-title":"Prevention of hepatitis b reactivation in patients requiring chemotherapy and immunosuppressive therapy","volume":"9","author":"Shih","year":"2021","journal-title":"World J Clin Cases."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis b virus infection: An update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of b-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis b patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3259","article-title":"The role of anti-HBs in hepatitis b reactivation during direct-acting antiviral therapy for chronic hepatitis c","volume":"23","author":"Spaan","year":"2018","journal-title":"Antivir Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2021.00051","article-title":"B cell-mediated humoral immunity in chronic hepatitis b infection","volume":"9","author":"Li","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25377","article-title":"HBcAg-induced upregulated 4-1BB ligand on b cells contributes to b-cell hyperactivation during chronic hepatitis b infection","volume":"91","author":"Liu","year":"2019","journal-title":"J Med Virol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104283","article-title":"Sorted b cell transcriptomes point towards actively regulated b cell responses during ongoing chronic hepatitis b infections","volume":"362","author":"Van Hees","year":"2021","journal-title":"Cell Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/gastro\/goaa048","article-title":"Skewed CD39\/CD73\/adenosine pathway contributes to b-cell hyperactivation and disease progression in patients with chronic hepatitis b","volume":"9","author":"Zhou","year":"2021","journal-title":"Gastroenterol Rep (Oxf)."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121957","article-title":"PD-1 blockade partially recovers dysfunctional virus-specific b cells in chronic hepatitis b infection","volume":"128","author":"Salimzadeh","year":"2018","journal-title":"J Clin Invest."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/aji.13083","article-title":"Chronic hepatitis b infection alters peripheral immune response in women with reproductive failure","volume":"81","author":"Li","year":"2019","journal-title":"Am J Reprod Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15202","article-title":"Hepatitis b virus-induced hyperactivation of b cells in chronic hepatitis b patients via TLR4","volume":"24","author":"Li","year":"2020","journal-title":"J Cell Mol Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.653198","article-title":"Regulatory b cells dysregulated T cell function in an IL-35-Dependent way in patients with chronic hepatitis b","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641362","article-title":"Increased circulating T follicular helper cells induced via IL-12\/21 in patients with acute on chronic hepatitis b liver failure","volume":"12","author":"Du","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.599648","article-title":"IL-21-Deficient T follicular helper cells support b cell responses through IL-27 in patients with chronic hepatitis b","volume":"11","author":"Khanam","year":"2020","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.735913","article-title":"(T(FH)) cell targeting by TLR8 signaling for improving HBsAg-specific b cell response in chronic hepatitis b patients","volume":"12","author":"Ayithan","year":"2021","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/srep26494","article-title":"ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination","volume":"6","author":"Bentebibel","year":"2016","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.10.020","article-title":"High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis b","volume":"56","author":"Ma","year":"2012","journal-title":"J Hepatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868616","article-title":"Editorial: Targeting the immune system to treat hepatitis b virus infection","volume":"13","author":"Meng","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12418","article-title":"Pegylated interferon alfa for chronic hepatitis b: systematic review and meta-analysis","volume":"23","author":"Kim","year":"2016","journal-title":"J Viral Hepat."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3390\/v14061128","article-title":"Novel pegylated interferon for the treatment of chronic viral hepatitis","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis b","volume":"58","author":"Micco","year":"2013","journal-title":"J Hepatol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005788","article-title":"Interferon alpha induces sustained changes in NK cell responsiveness to hepatitis b viral load suppression","volume":"12","author":"Gill","year":"2016","journal-title":"In Vivo. PloS Pathog"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2178143","article-title":"The characteristics of natural killer cells in chronic hepatitis b patients who received PEGylated-interferon versus entecavir therapy","volume":"2021","author":"Cao","year":"2021","journal-title":"BioMed Res Int"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e160171","DOI":"10.1371\/journal.pone.0160171","article-title":"Altered immune profiles of natural killer cells in chronic hepatitis b patients: A systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis b","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41467-021-22967-7","article-title":"Targeting human acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint","volume":"12","author":"Schmidt","year":"2021","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93024","article-title":"Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis b virus infection","volume":"127","author":"Kah","year":"2017","journal-title":"J Clin Invest."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.10.013","article-title":"Restoration of T cell function in chronic hepatitis b patients upon treatment with interferon based combination therapy","volume":"64","author":"de Niet","year":"2016","journal-title":"J Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01561","article-title":"Hepatitis b virus adaptation to the CD8+ T cell response: Consequences for host and pathogen","volume":"9","author":"Lumley","year":"2018","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-021-00776-0","article-title":"Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-\u03b1 therapy","volume":"6","author":"Wang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/hep.31695","article-title":"Therapeutic potential of TLR8 agonist GS-9688 (Selgantolimod) in chronic hepatitis b: Remodeling of antiviral and regulatory mediators","volume":"74","author":"Amin","year":"2021","journal-title":"Hepatology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3851\/IMP2953","article-title":"Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB","volume":"20","author":"Yan","year":"2015","journal-title":"Antivir Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab216","article-title":"Pegylated interferon-a (IFN-a) enhances the inhibitory effect of natural killer cells on regulatory T cells via IFN-\u03b3 in chronic hepatitis b","volume":"224","author":"Yuan","year":"2021","journal-title":"J Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2013.0032","article-title":"Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis b","volume":"26","author":"Hao","year":"2013","journal-title":"Viral Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.intimp.2018.06.043","article-title":"Recovery of circulating CD56(dim) NK cells and the balance of Th17\/Treg after nucleoside analog therapy in patients with chronic hepatitis b and low levels of HBsAg","volume":"62","author":"Liu","year":"2018","journal-title":"Int Immunopharmacol."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.5604\/16652681.1193705","article-title":"Effect of entecavir on CD4+ T-cell subpopulations in patients with chronic hepatitis b","volume":"15","author":"Tian","year":"2016","journal-title":"Ann Hepatol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/143026","article-title":"Th1 and Th2 immune response in chronic hepatitis b patients during a long-term treatment with adefovir dipivoxil","volume":"2010","author":"Jiang","year":"2010","journal-title":"Mediators Inflamm"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv180","article-title":"Natural killer cell characteristics in patients with chronic hepatitis b virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon Alfa-2a and adefovir","volume":"212","author":"Stelma","year":"2015","journal-title":"J Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156200","article-title":"Remodeling of b-cell subsets in blood during pegylated IFN\u03b1-2a therapy in patients with chronic hepatitis b infection","volume":"11","author":"Aspord","year":"2016","journal-title":"PloS One"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis b core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis b patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12626","article-title":"Baseline hepatitis b core antibody predicts treatment response in chronic hepatitis b patients receiving long-term entecavir","volume":"24","author":"Xu","year":"2017","journal-title":"J Viral Hepat."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac210","article-title":"Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis b patients","author":"Brakenhoff","year":"2022","journal-title":"J Infect Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1177\/1753425920942580","article-title":"Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy","volume":"26","author":"Cao","year":"2020","journal-title":"Innate Immun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893628","article-title":"Effect of antiviral therapy during pregnancy on natural killer cells in pregnant women with chronic HBV infection","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/cei.13486","article-title":"Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis b patients","volume":"202","author":"Pang","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-021-01812-0","article-title":"HBeAg-positive patients with HBsAg \u2009<\u2009100 IU\/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation","volume":"56","author":"Xie","year":"2021","journal-title":"J Gastroenterol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859430","article-title":"Clinical utility of SCALE-b to predict hepatitis b virus relapse, hepatitis b surface antigen loss after antiviral cessation in Asian patients after 2-year follow-up","volume":"9","author":"Kaewdech","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis b: An international, multicenter, multiethnic cohort (RETRACT-b study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy097","article-title":"Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis b is associated with liver damage and HBsAg loss","volume":"217","author":"Zimmer","year":"2018","journal-title":"J Infect Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis b patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.04.006","article-title":"Perspectives and limitations for nucleo(t)side analogs in future HBV therapies","volume":"30","author":"Levrero","year":"2018","journal-title":"Curr Opin Virol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10095-1","article-title":"Efficacy of peg-interferon-nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB","volume":"15","author":"Xu","year":"2021","journal-title":"Hepatol Int"},{"key":"B87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","article-title":"End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after peg-IFN-based therapy in patients with CHB","volume":"77","author":"Huang","year":"2022","journal-title":"J Hepatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00535-021-01840-w","article-title":"T Follicular helper cells improve the response of patients with chronic hepatitis b to interferon by promoting HBsAb production","volume":"57","author":"Liu","year":"2022","journal-title":"J Gastroenterol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2019.0042","article-title":"Boosting of hepatitis b virus-specific T cell responses after pegylated-Interferon-\u03b1-2a therapy for hepatitis b e antigen-positive pediatric patients","volume":"39","author":"Ning","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02308","article-title":"Toward a functional cure for hepatitis b: The rationale and challenges for therapeutic targeting of the b cell immune response","volume":"10","author":"Ma","year":"2019","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.058","article-title":"Investigation of memory b cell responses to hepatitis b surface antigen in health care workers considered as non-responders to vaccination","volume":"28","author":"Valats","year":"2010","journal-title":"Vaccine."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1086\/591094","article-title":"Direct ex vivo evaluation of long-lived protective antiviral memory b cell responses against hepatitis b virus","volume":"198","author":"Ward","year":"2008","journal-title":"J Infect Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral b cells are defective in hepatitis b","volume":"128","author":"Burton","year":"2018","journal-title":"J Clin Invest."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis b surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis b e antigen-negative chronic hepatitis b","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology."},{"key":"B95","doi-asserted-by":"publisher","first-page":"13383","DOI":"10.1038\/s41598-017-13747-9","article-title":"Switching to PegIFN\u03b1-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9890-x","article-title":"Multiple doses of hepatitis b recombinant vaccine for chronic hepatitis b patients with low surface antigen levels: a pilot study","volume":"12","author":"Lai","year":"2018","journal-title":"Hepatol Int"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09956-1","article-title":"Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis b patients: the endeavor study","volume":"13","author":"Wu","year":"2019","journal-title":"Hepatol Int"},{"key":"B98","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4172\/2332-0877.1000390","article-title":"Induction of functional control in chronic hepatitis b patients with low level HBsAg using a combination of a PreS1\/S2\/S HBV vaccine (Sci-BVacTM) and a nucleoside analogue","volume":"7","author":"Roggendorf","year":"2019","journal-title":"J Infect Dis Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03127","article-title":"Advances in targeting the innate and adaptive immune systems to cure chronic hepatitis b virus infection","volume":"10","author":"Meng","year":"2019","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101969","article-title":"Suppression of hepatitis b virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes","volume":"24","author":"Lee","year":"2021","journal-title":"iScience."},{"key":"B101","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41423-021-00801-w","article-title":"STING signaling activation inhibits HBV replication and attenuates the severity of liver injury and HBV-induced fibrosis","volume":"19","author":"Li","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis b virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32614","article-title":"Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis b","author":"Xu","year":"2022","journal-title":"Hepatology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.016","article-title":"Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis b","volume":"65","author":"Lok","year":"2016","journal-title":"J Hepatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.03.044","article-title":"Combined GS-4774 and tenofovir therapy can improve HBV-specific T-cell responses in patients with chronic hepatitis","volume":"157","author":"Boni","year":"2019","journal-title":"Gastroenterology."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30090-8","article-title":"PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection","volume":"70","author":"Lim","year":"2019","journal-title":"J Hepatol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"S854","DOI":"10.1016\/S0168-8278(22)02005-0","article-title":"SAT403 - induction of pre-s antobodies in HBeAg negative chronic hepatitis b patients by thereupatic vaccination with the pre-s based vaccine VVX001-interim analysis","volume":"77","author":"Munda","year":"2022","journal-title":"J Hepatol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100361","article-title":"Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study","volume":"3","author":"Ma","year":"2021","journal-title":"JHEP Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30944-2","article-title":"FRI-199-First in human, single ascending dose clinical trial of AIC649 in patients with chronic hepatitis","volume":"70","author":"Addy","year":"2019","journal-title":"J Hepatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12530","article-title":"Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice","volume":"35","author":"Yoon","year":"2015","journal-title":"Liver Int"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S868","DOI":"10.1016\/S0168-8278(22)02030-X","article-title":"SAT428 - phase 1b\/2a study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos (t)ide analogues","volume":"77","author":"Evans","year":"2022","journal-title":"J Hepatol"},{"key":"B112","article-title":"VRON-0200, a therapeutic HBV vaccine with an intrinsic checkpoint inhibitor elicits broad CD8+T cell responses and sustained antiviral declines in preclinical studies","volume":"75","author":"Hasanpourghadi","year":"2021","journal-title":"J Hepatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)00541-4","article-title":"Therapeutic vaccine JNJ-0535 induces a strong HBV-specific T-cell response in healthy adults and a modest response in chronic HBV-infected patients","volume":"77","author":"De Creus","year":"2022","journal-title":"J Hepatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1689080","article-title":"A dendritic cell receptor-targeted chimeric immunotherapeutic protein (C-HBV) for the treatment of chronic hepatitis b","volume":"16","author":"Ma","year":"2020","journal-title":"Hum Vacc Immunother."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1689081","article-title":"A dendritic cell-targeted chimeric hepatitis b virus immunotherapeutic vaccine induces both cellular and humoral immune responses in vivo","volume":"16","author":"George","year":"2020","journal-title":"Hum Vacc Immunother."},{"key":"B116","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/biom12030470","article-title":"PD-L1 silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis b","volume":"12","author":"Bunse","year":"2022","journal-title":"BIOMOLECULES."},{"key":"B117","doi-asserted-by":"publisher","first-page":"S834","DOI":"10.1016\/S0168-8278(22)01964-X","article-title":"Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis b induces anti-HBs responses associated with functional cure","volume":"77","author":"Walsh","year":"2022","journal-title":"J Hepatol"},{"key":"B118","article-title":"Safety and efficacy of oral TLR8 agonist, selgantolimod, in viremic adult patients with chronic hepatitis b","volume":"75","author":"Janssen","year":"2021","journal-title":"J Hepatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00100","article-title":"Discovery of GS-9688 (Selgantolimod) as a potent and selective oral toll-like receptor 8 agonist for the treatment of chronic hepatitis b","volume":"63","author":"Mackman","year":"2020","journal-title":"J Med Chem"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12791","article-title":"A single and multiple ascending dose study of toll-like receptor 7 agonist (RO7020531) in Chinese healthy volunteers","volume":"13","author":"Luk","year":"2020","journal-title":"Cts-Clin Transl Sci"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1873275","article-title":"Safety, pharmacokinetics and pharmacodynamics of TQ-A3334, an oral toll-like receptor 7 agonist in healthy individuals","volume":"30","author":"Hu","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"B122","article-title":"SBT8230, an asgr1-directed tlr8 immunotac therapeutic for the treatment of chronic hepatitis b virus, demonstrates favorable preclinical tolerability with liver-localized activity","volume":"74","author":"Jang","year":"2021","journal-title":"Hepatology."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)30572-9","article-title":"Targeting inhibitor of apoptosis proteins (IAPs) enhances intrahepatic antiviral immunity to clear hepatitis b virus infection","volume":"73","author":"Zhang","year":"2020","journal-title":"vivo. J Hepatol"},{"key":"B124","article-title":"A prospective, open-label, dose-escalation, single-center, phase 1 study for GC1102, a recombinant human immunoglobulin for chronic hepatitis b patients","volume":"68","author":"Lee","year":"2018","journal-title":"Hepatology."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)01959-6","article-title":"Dose-dependent durability of hepatitis b surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody","volume":"77","author":"Agarwal","year":"2022","journal-title":"J Hepatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/S0168-8278(22)00538-4","article-title":"ALT flares were linked to HBsAg reduction, seroclearance and seroconversion: interim results from a phase IIb study in chronic hepatitis b patients with 24-week treatment of subcutaneous PD-L1 ab ASC22 (Envafolimab) plus nucleos (t)ide analogs","volume":"77","author":"Wang","year":"2022","journal-title":"J Hepatol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"S848","DOI":"10.1016\/S0168-8278(22)01993-6","article-title":"Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis b patients","volume":"77","author":"Thi","year":"2022","journal-title":"J Hepatol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"S853","DOI":"10.1016\/S0168-8278(22)02003-7","article-title":"Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis b","volume":"77","author":"Wu","year":"2022","journal-title":"J Hepatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(22)02039-6","article-title":"IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study","volume":"77","author":"Bourgeois","year":"2022","journal-title":"J Hepatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00207","article-title":"The PD-1\/PD-L1 axis and virus infections: A delicate balance","volume":"9","author":"Sch\u00f6nrich","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.648420","article-title":"Functional exhaustion of HBV-specific CD8 T cells impedes PD-L1 blockade efficacy in chronic HBV infection","volume":"12","author":"Ferrando-Martinez","year":"2021","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i7.2294","article-title":"Role of Tim-3 in hepatitis b virus infection: An overview","volume":"22","author":"Liu","year":"2016","journal-title":"World J Gastroenterol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2018.3688","article-title":"CTLA\u22124 interferes with the HBV\u2212specific T cell immune response (Review)","volume":"42","author":"Cao","year":"2018","journal-title":"Int J Mol Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000005275","article-title":"Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis b: A balance between immunity strength and liver injury extent","volume":"96","author":"Ye","year":"2017","journal-title":"Med (Baltimore)."},{"key":"B135","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","article-title":"HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice","volume":"20","author":"Kruse","year":"2018","journal-title":"Cytotherapy."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis b vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J Infect Dis"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S317113","article-title":"Chitosan nanovaccines as efficient carrier adjuvant system for IL-12 with enhanced protection against HBV","volume":"16","author":"Zhao","year":"2021","journal-title":"Int J Nanomedicine."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2008.00468.x","article-title":"HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis b virus-specific cytotoxic T lymphocytes","volume":"39","author":"Chen","year":"2009","journal-title":"Hepatol Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.079","article-title":"Hepatitis b surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis b infection","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine."},{"key":"B140","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/pathogens10111440","article-title":"Sustained antiviral and liver protection by a nasal therapeutic vaccine (NASVAC, containing both HBsAg and HBcAg) in patients with chronic hepatitis b: 2-year follow-up of phase III clinical trial","volume":"10","author":"Akbar","year":"2021","journal-title":"Pathogens."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01032-19","article-title":"Revisiting hepatitis b virus: Challenges of curative therapies","volume":"93","author":"Hu","year":"2019","journal-title":"J Virol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1357","article-title":"Immune determinants in the acquisition and maintenance of antibody to hepatitis b surface antigen in adults after first-time hepatitis b vaccination","volume":"3","author":"Doi","year":"2019","journal-title":"Hepatol Commun"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1319021","article-title":"Antibody-mediated immunotherapy against chronic hepatitis b virus infection","volume":"13","author":"Gao","year":"2017","journal-title":"Hum Vaccin Immunother."},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-016-1189-x","article-title":"Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis b infection","volume":"51","author":"Tsuge","year":"2016","journal-title":"J Gastroenterol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1002\/jmv.27926","article-title":"Longitudinal mapping of hepatitis b vaccine-induced b-cell linear epitopes in healthy individuals","volume":"94","author":"Zhong","year":"2022","journal-title":"J Med Virol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.733364","article-title":"Interferon and hepatitis b: Current and future perspectives","volume":"12","author":"Ye","year":"2021","journal-title":"Front Immunol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/hep.31282","article-title":"Functional comparison of interferon-\u03b1 subtypes reveals potent hepatitis b virus suppression by a concerted action of interferon-\u03b1 and interferon-\u03b3 signaling","volume":"73","author":"Chen","year":"2021","journal-title":"Hepatology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis b: Novel therapeutic targets for hepatitis b virus","volume":"28","author":"Kim","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2000.02099.x","article-title":"Treatment of chronic hepatitis b virus infection: who, when, what for and how","author":"Liaw","year":"2000","journal-title":"J Gastroenterol Hepatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.02.020","article-title":"Immunological biomarker discovery in cure regimens for chronic hepatitis b virus infection","volume":"77","author":"Gehring","year":"2022","journal-title":"J Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1075916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T10:25:30Z","timestamp":1668680730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1075916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":150,"alternative-id":["10.3389\/fimmu.2022.1075916"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1075916","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"article-number":"1075916"}}